Literature DB >> 24814139

A recently-discovered NMDA receptor gene, GRIN3B, is associated with duration mismatch negativity.

Yi-Ting Lin1, Ming H Hsieh2, Chen-Chung Liu3, Tzung-Jeng Hwang3, Yi-Ling Chien4, Hai-Gwo Hwu3, Chih-Min Liu5.   

Abstract

The study explored associations between mismatch negativity and N-methyl-d-aspartic acid receptor subunit genes, GRIN1, GRIN2B and GRIN3B in healthy subjects and schizophrenia. Nineteen single-nucleotide polymorphisms were genotyped in 138 schizophrenia patients and 103 healthy subjects. Rs2240158 of GRIN3B was significantly associated with mismatch negativity in healthy subjects.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Glutamate; Mismatch negativity; Schizophrenia

Mesh：

Substances：

Year:  2014        PMID： 24814139     DOI： 10.1016/j.psychres.2014.04.032

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN： 0165-1781            Impact factor:   3.222


  8 in total

1.  Meta-analysis of mismatch negativity to simple versus complex deviants in schizophrenia.

Authors:  Michael Avissar; Shanghong Xie; Blair Vail; Javier Lopez-Calderon; Yuanjia Wang; Daniel C Javitt
Journal:  Schizophr Res       Date:  2017-07-11       Impact factor: 4.939

2.  Global analysis of H3K27me3 as an epigenetic marker in prostate cancer progression.

Authors:  Marjolaine Ngollo; Andre Lebert; Marine Daures; Gaelle Judes; Khaldoun Rifai; Lucas Dubois; Jean-Louis Kemeny; Frederique Penault-Llorca; Yves-Jean Bignon; Laurent Guy; Dominique Bernard-Gallon
Journal:  BMC Cancer       Date:  2017-04-12       Impact factor: 4.430

3.  Rare loss of function mutations in N-methyl-D-aspartate glutamate receptors and their contributions to schizophrenia susceptibility.

Authors:  Yanjie Yu; Yingni Lin; Yuto Takasaki; Chenyao Wang; Hiroki Kimura; Jingrui Xing; Kanako Ishizuka; Miho Toyama; Itaru Kushima; Daisuke Mori; Yuko Arioka; Yota Uno; Tomoko Shiino; Yukako Nakamura; Takashi Okada; Mako Morikawa; Masashi Ikeda; Nakao Iwata; Yuko Okahisa; Manabu Takaki; Shinji Sakamoto; Toshiyuki Someya; Jun Egawa; Masahide Usami; Masaki Kodaira; Akira Yoshimi; Tomoko Oya-Ito; Branko Aleksic; Kinji Ohno; Norio Ozaki
Journal:  Transl Psychiatry       Date:  2018-01-10       Impact factor: 6.222

4.  Impacts of GRIN3A, GRM6 and TPH2 genetic polymorphisms on quality of life in methadone maintenance therapy population.

Authors:  Ruey-Yun Wang; Hsiu-Ju Chen; Chieh-Liang Huang; Jiun-Yi Wang; Tsui-Er Lee; Hsiang-Yen Lee; Chin-Chuan Hung
Journal:  PLoS One       Date:  2018-07-30       Impact factor: 3.240

5.  GRIN3B missense mutation as an inherited risk factor for schizophrenia: whole-exome sequencing in a family with a familiar history of psychotic disorders.

Authors:  Tobias Hornig; Björn Grüning; Kousik Kundu; Torsten Houwaart; Rolf Backofen; Knut Biber; Claus Normann
Journal:  Genet Res (Camb)       Date:  2017-01-30       Impact factor: 1.588

6.  Association of CaMK2A and MeCP2 signaling pathways with cognitive ability in adolescents.

Authors:  Li-Ching Lee; Ming-Tsan Su; Hsing-Ying Huang; Ying-Chun Cho; Ting-Kuang Yeh; Chun-Yen Chang
Journal:  Mol Brain       Date:  2021-10-04       Impact factor: 4.041

7.  Transcriptome-wide association study of post-trauma symptom trajectories identified GRIN3B as a potential biomarker for PTSD development.

Authors:  Adriana Lori; Katharina Schultebraucks; Isaac Galatzer-Levy; Nikolaos P Daskalakis; Seyma Katrinli; Alicia K Smith; Amanda J Myers; Ryan Richholt; Matthew Huentelman; Guia Guffanti; Stefan Wuchty; Felicia Gould; Philip D Harvey; Charles B Nemeroff; Tanja Jovanovic; Ekaterina S Gerasimov; Jessica L Maples-Keller; Jennifer S Stevens; Vasiliki Michopoulos; Barbara O Rothbaum; Aliza P Wingo; Kerry J Ressler
Journal:  Neuropsychopharmacology       Date:  2021-06-29       Impact factor: 8.294

8.  A naturally occurring null variant of the NMDA type glutamate receptor NR3B subunit is a risk factor of schizophrenia.

Authors:  Hitomi Matsuno; Kazutaka Ohi; Ryota Hashimoto; Hidenaga Yamamori; Yuka Yasuda; Michiko Fujimoto; Satomi Yano-Umeda; Takeo Saneyoshi; Masatoshi Takeda; Yasunori Hayashi
Journal:  PLoS One       Date:  2015-03-13       Impact factor: 3.240
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.